Atrium Therapeutics SEC Filings
NASDAQ: RNAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
8.40+0.14 (+1.69%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Atrium Therapeutics filing overview
This page lists 2 recent SEC filings by Atrium Therapeutics (RNA), including 1 8-K/A, 1 8-K. The latest current report (8-K), used to disclose material events such as earnings releases and executive changes, was filed on Oct 9, 2026. Form 10-K is the audited annual report, 10-Q the quarterly report, 8-K covers material events, and Form 4 reports insider transactions. All documents link directly to SEC EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
RNA SEC filings
| Filed | Form | Description | Document |
|---|---|---|---|
| Oct 9, 2026 | 8-K/A | Amended: Other Events | View on EDGAR |
| Oct 8, 2026 | 8-K | Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events | View on EDGAR |